The interim recommendation made by the National Drug Scheduling Advisory Committee (NDSAC) on September 15, 2024 that:

• Nirsevimab be granted Schedule II status

was finalized effective November 5, 2024. Final approval of the interim recommendation was made by NAPRA’s Board of Directors. In this case, NAPRA did not receive any comments during the 30-day consultation period. The National Drug Schedules will be revised accordingly.